

| 論文全著者名. 論題. 雑誌名. 発行年; 巻 :始頁-終頁 | 著者名 |
|--|---|
| Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report. Thoracic Cancer. 2019 May;10(5):1276-1279. doi: 10.1111/1759-7714.13065. Epub 2019 Apr 9. | Edahiro R, Ishijima M, Kurebe H, Nishida K, Uenami T, Kanazu M, Akazawa Y, Yano Y, Mori M. |
| Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. | Edahiro R, Kanazu M, Kurebe H, Mori M, Fujimoto D, Taniguchi Y, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T, Tamiya M. |
| Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis. Thorac Cancer. 2019 Nov;10(11):2183-2187. doi: 10.1111/1759-7714.13197. Epub 2019 Sep 14. | Osa A, Uenami T, Naito Y, Hirata H, Koyama S, Takimoto T, Shiroyama T, Futami S, Nakatsubo S, Sawa N, Yano Y, Nagatomo I, Takeda Y, Mori M, Kida H, Kumanogoh A. |
| Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs. 2019 Dec;37(6):1266-1273. doi: 10.1007/s10637-019-00843-y. Epub 2019 Aug 7. | Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D. |
| Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Invest New Drugs. 2020 Feb;38(1):211-218. doi: 10.1007/s10637-019-00882-5. Epub 2019 Nov 30. | Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto D, Hosoya K, Suzuki H, Hirashima T, Kanazu M, Sawa N, Uchida J, Morita M, Makio T, Hara S, Kumagai T. |
| Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep. 2019 Dec 3;9(1):18202. doi: 10.1038/s41598-019-54804-9. | Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S. |
| Prediction of patients with a tumor proportion score>50% who do not respond to first-line monotherapy with pembrolizumab. BMC Cancer. 2020 Feb 3;20(1):93. doi: 10.1186/s12885-020-6582-4. | Morita M, Tamiya M, Fujimoto D, Tamiya A, Suzuki H, Hirano K, Fukuda Y, Yokoyama T, Kominami R, Kanazu M, Uchida J, Hara S, Yamashita S, Tomioka H. |
| Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin Lung Cancer. 2020 Feb 4. pii: S1525-7304(20)30003-6. doi: 10.1016/j.clcc.2020.01.003. [Epub ahead of print] | Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M. |

| | |
|--|--|
| <p>Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L). J Immunother Cancer. 2020 Feb;8(1). pii: e000350. doi: 10.1136/jitc-2019-000350.</p> | <p>Kato R, Hayashi H, Chiba Y, Miyawaki E, Shimizu J, Ozaki T, Fujimoto D, Toyozawa R, Nakamura A, Kozuki T, Tanaka K, Teraoka S, Usui K, Nishino K, Hataji O, Ota K, Ebi N, Saeki S, <u>Akazawa Y</u>, Okuno M, Yamamoto N, Nakagawa K.</p> |
| <p>1. 肺癌薬物療法で免疫治療薬が主役になりました. 豊中市医師会月報 2019年7月 メディカル・トピックス</p> | <p>森 雅秀</p> |